OR WAIT null SECS
HTL Biotechnology and Echelon Biosciences have formed a strategic partnership for the distribution of high-quality HA and GAG, and the co-development of novel GAG products.
HTL Biotechnology and Echelon Biosciences have formed a strategic partnership for the distribution of high-quality hyaluronic acid (HA) and glycosaminoglycan (GAG), and the co-development of novel GAG products. The partnership was revealed in an April 14, 2021 press release.
The partnership will enable academic research and pharmaceutical development laboratories to gain expanded access to good manufacturing practice (GMP)-grade, kit-packaged HA and GAG products. The goal of the partnership, and the provision of clinical grade products to early-stage researchers, is to bridge the gap between lab-based research, development, and commercialization.
“Innovation is at the heart of HTL’s DNA,” said Yvon Bastard, CEO, HTL, in the press release. “This growth opportunity reinforces our mission and vision to apply science for increased bio-compatibility and improved health outcomes around the world.”
“This new partnership offers scientists and researchers the key technologies to develop innovative biopolymer solutions for new medical applications in aesthetics, ophthalmology, rheumatology, tissue engineering, and drug delivery,” added Charles Ruban, deputy CEO, HTL, in the press release.
“Echelon has been granted the opportunity to expand its market-leading HA assays and extra cellular matrix product line with the supply of HTL’s HA and other GAG-derived products. HTL is recognized internationally for producing biopolymers of premium quality,” stated Bert Israelsen, president of Echelon Biosciences, in the press release.